Skip to main content

Advertisement

SpringerLink
Log in

Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

The present study evaluated baseline patient- or tumor-related prognostic factors in patients with advanced gastric adenocarcinoma.

Patients and methods

A total of 304 consecutive patients with newly diagnosed metastatic or recurrent gastric cancer treated with one or more cycles of cisplatin-based chemotherapy at the Korea Cancer Center Hospital were enrolled in the current study.

Results

Among the original 304 patients, only 4 patients were alive at the time of this analysis. The median survival for all patients was 7.3 (95% CI, 6.3–8.2) months. Five independent prognostic factors were identified by a multivariate analysis: poor performance status (hazard ratio [HR], 1.46; 95% CI, 1.32–2.92), elevated total bilirubin (HR, 2.04; 95% CI, 1.73–2.35), presence of peritoneal metastasis (HR, 1.73; 95% CI, 1.57–1.90), presence of bone metastasis (HR, 3.11; 95% CI, 2.69–3.53), and more than 1 metastatic site (HR, 1.22; 95% CI, 1.06–1.38). A prognostic index was constructed that divided the patients into a good (n = 162), moderate (n = 82), or poor (n = 60) risk group. The 1-year survival rates for the good, moderate, and poor risk groups were 34.6, 20.7, and 1.7%, respectively, and the survival differences among the groups were highly significant (P < 0.0001).

Conclusion

Five prognostic factors were identified from patients receiving first-line cisplatin-based chemotherapy for advanced gastric cancer. A simple prognostic index was then developed that produced distinct survival rates among the different risk groups. Therefore, this prognostic model could help clinicians and patients in clinical decision-making and treatment tailoring based on the estimated prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Pisani P, Parkin DM, Bray F, Ferlay J (1999) Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83:18–29

    Article  PubMed  CAS  Google Scholar 

  2. Ries LAG, Eisner MP, Kosary CL (2004) SEER cancer statistics review, 1975–2001, National Cancer Institute, Bethesda

  3. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37–41

    Article  PubMed  CAS  Google Scholar 

  4. Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M (1995) Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587–591

    PubMed  CAS  Google Scholar 

  5. Glimelius B, Hoffmann K, Haglund U, Nyrén O, Sjödén PO (1994) Initial or delayed chemotherapy with best supportive in advanced gastric cancer. Ann Oncol 5:189–190

    PubMed  CAS  Google Scholar 

  6. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, Kang YK, Shin DB, Kim HT, Kim HJ (1993) A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71:3813–3818

    Article  PubMed  CAS  Google Scholar 

  7. Kim TW, Kang YK, Ahn JH, Chang HM, Yook JH, Oh ST, Kim BS, Lee JS (2002) Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol 13:1893–1898

    Article  PubMed  CAS  Google Scholar 

  8. Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, Morant R, Borner MM, Herrmann R, Honegger H, Cavalli F, Alberto P, Castiglione M, Goldhirsch A (2000) Docetaxel (Taxotere)-cisplatin (TC): An effective drug combination in gastric carcinoma. Ann of Oncol 11:301–306

    Article  CAS  Google Scholar 

  9. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, Sakata Y, Hyodo I (1999) Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17:319–323

    PubMed  CAS  Google Scholar 

  10. Tsujitani S, Oka S, Suzuki K, Saito H, Kondo A, Ikeguchi M, Maeta M, Kaibara N (2001) Prognostic factors in patients with advanced gastric cancer treated with by noncurative resection: a multivariate analysis. Hepatogastroenterology 48:1504–1508

    PubMed  CAS  Google Scholar 

  11. Tas F, Aykan NF, Aydiner A, Uygun K, Basaran M, Camlica H, Topuz E (2000) The roles of chemotherapy and surgery in gastric carcinoma and the influence of prognostic factors on survival. Am J Clin Oncol 23:53–57

    Article  PubMed  CAS  Google Scholar 

  12. Bedikian AY, Chen TT, Khankhanian N, Heilbrun LK, McBride CM, McMurtrey MJ, Bodey GP (1984) The natural history of gastric cancer and prognostic factors influencing survival. J Clin Oncol 2:305–310

    PubMed  CAS  Google Scholar 

  13. Louvet C, Carrat F, Mal F, Mabro M, Beerblock K, Vaillant JC, Cady J, Andre T, Gamelin E, de Gramont A (2003) Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen). Cancer invest 21:14–20

    Article  PubMed  CAS  Google Scholar 

  14. Rougier P, Ducreux M, Mahjoubi M, Pignon JP, Bellefqih S, Oliveira J, Bognel C, Lasser P, Ychou M, Elias D (1994) Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factor analysis. Eur J Cancer 30:1263–1269

    Article  Google Scholar 

  15. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ (2004) Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-Pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 22:2395–2403

    Article  PubMed  Google Scholar 

  16. World Health Organization (1979) WHO handbook for reporting results of cancer treatment, WHO Offset Publ., No. 4. World Health Organization, Geneva

  17. Gallo A, Cha C (2006) Updates on esophageal and gastric cancers. World J Gastroenterol 2006:3237–3242

    Google Scholar 

  18. Engel LS, Chow WH, Vaughan TL, Gammon MD, Risch HA, Stanford JL, Schoenberg JB, Mayne ST, Dubrow R, Rotterdam H, West AB, Blaser M, Blot WJ, Gail MH, Fraumeni JF Jr (2003) Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 95:1404–1413

    PubMed  Google Scholar 

  19. Mitry E, Douillard JY, van Cutsem E, Cunningham D, Magherini E, Mery-Mignard D, Awad L, Rougier P (2004) Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trial. Ann Oncol 15:1013–1017

    Article  PubMed  CAS  Google Scholar 

  20. Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH (2005) Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data. J Clin Oncol 23:175–183

    Article  PubMed  CAS  Google Scholar 

  21. A Predictive Model for Aggressive Non-Hodgkin’s Lymphoma (1993) The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 329:987–994

    Article  Google Scholar 

  22. Andreyev HJ, Norman AR, Oates J, Cunningham D (1998) Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 34:503–509

    Article  PubMed  CAS  Google Scholar 

  23. Kienle P, Koch M (2002) Are “micrometastases” of the peritoneum equivalent to distant metastases? Dis Surg 19:453–458

    Article  Google Scholar 

  24. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21:3737–3743

    Article  PubMed  Google Scholar 

  25. Yu W, Whang I, Suh I, Averbach A, Chang D, Sugarbaker PH (1998) Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 228:347–354

    Article  PubMed  CAS  Google Scholar 

  26. Etoh T, Baba H, Taketomi A, Nakashima H, Kohnoe S, Seo Y, Fukuda T, Tomoda H (1999) Diffuse bone metastasis with hematologic disorders from gastric cancer : clinicopathological features and prognosis. Oncol Rep 6:601–605

    PubMed  CAS  Google Scholar 

  27. Chu KM, Law S, Branicki FJ, Wong J (1998) Extrahepatic biliary obstruction by metastatic gastric carcinoma. J Clin Gastroenterol 27:63–66

    Article  PubMed  CAS  Google Scholar 

  28. Baek JH, Kim JG, Jeon SB, Chae YS, Kim DH, Sohn SK, Lee KB, Choi YJ, Shin HJ, Chung JS, Cho GJ, Chung HY, Yu W (2006) Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer. Br J Cancer 94:1407–1411

    Article  PubMed  CAS  Google Scholar 

  29. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA; V325 Study Group (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991–4997

    Article  PubMed  Google Scholar 

  30. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Salas MP, Suarez T, Santamaria J (2006) Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients with advanced gastric cancer. J Clin Oncol 24:4018a

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology-Oncology, Korea Cancer Center Hospital, Seoul, South Korea

    Jong Gwang Kim, Baek-Yeol Ryoo, Yeon Hee Park, Bong-Seog Kim, Tae-You Kim, Young-Hyuck Im & Yoon-Koo Kang

  2. Department of Oncology/Hematology, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu, South Korea

    Jong Gwang Kim

  3. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea

    Yeon Hee Park & Young-Hyuck Im

  4. Department of Internal Medicine, Division of Haematology and Oncology, Seoul Veterans Hospital, Seoul, South Korea

    Bong-Seog Kim

  5. Department of Internal Medicine, Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea

    Tae-You Kim

  6. Division of Oncology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, 388-1, Poongnap-dong, Songpa-gu, Seoul, South Korea

    Yoon-Koo Kang

Authors
  1. Jong Gwang Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Baek-Yeol Ryoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yeon Hee Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bong-Seog Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tae-You Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Young-Hyuck Im
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoon-Koo Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoon-Koo Kang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, J.G., Ryoo, BY., Park, Y.H. et al. Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol 61, 301–307 (2008). https://doi.org/10.1007/s00280-007-0476-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-007-0476-x

Keywords

Search

Navigation